Passage Bio inc   (PASG)
Other Ticker:  
Price: $1.6900 $-0.02 -1.170%
Day's High: $1.71 Week Perf: 14.97 %
Day's Low: $ 1.59 30 Day Perf: 72.45 %
Volume (M): 591 52 Wk High: $ 1.74
Volume (M$): $ 998 52 Wk Avg: $0.90
Open: $1.65 52 Wk Low: $0.58

 Market Capitalization (Millions $) 93
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -112
 Cash Flow (TTM) (Millions $) -29
 Capital Exp. (TTM) (Millions $) 1

Passage Bio Inc
Passage Bio Inc. is a genetic medicines company that specializes in developing transformative therapies for rare, monogenic central nervous system (CNS) disorders. The company utilizes its proprietary gene therapy platform to develop innovative treatments that target the underlying causes of these genetic disorders. By harnessing the power of genetic medicine, Passage Bio aims to provide long-lasting and potentially curative therapies that can significantly improve the lives of patients suffering from these rare diseases. The company's pipeline includes multiple product candidates at different stages of development, with a focus on conditions such as GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Passage Bio is committed to advancing its pipeline and partnering with experts, researchers, and patient communities to accelerate the development and delivery of life-changing treatments for rare genetic disorders.

   Company Address: One Commerce Square Philadelphia 19103 PA
   Company Phone Number: 866-0311   Stock Exchange / Ticker: NASDAQ PASG
   PASG is expected to report next financial results on March 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Frontiers in Neurodegenerative Disease Therapy: Passage Bio's PBFT02 Role in Potential Treatment for FTD-GRN

Published Wed, Dec 20 2023 12:00 PM UTC

The biotech sector is witnessing a significant development in the quest to combat neurodegenerative diseases. Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company, has announced initial safety and biomarker data from the Phase 1/2 trial of PBFT02, a pioneering gene therapy. The goal is to develop a disease-modifying therapy for patients with fron...

Passage Bio Inc

Passage Bio Inc Witnesses Remarkable Surge in Outlays During Fiscal Quarter Ending September 2023

The biotechnology and pharmaceuticals sector consultants have recently taken a closer look at the financial performance of Passage Bio Inc during the third quarter of 2023. The company has reported an operating loss of $-28.672 million, without generating any revenue during this reporting period from July to September 30, 2023. This is a concerning situation for the organization, as it indicates a lack of profitability and potential financial instability.
Comparing these figures to the previous year, Passage Bio Inc also experienced a significant operating loss during the third quarter of 2022, amounting to $-27.526 million. The net loss for the third quarter of 2023 has further increased to $-27.110 million, compared to $-26.701 million in the same period of 2022. These consistent losses demonstrate a worrying trend for the company and raise questions about its ability to generate sustainable revenue and profitability.


Passage Bio Grants Inducement Awards to New Employees, Demonstrating Commitment to Transformative Therapies for CNS Disorders

Published Fri, Oct 20 2023 8:30 PM UTC

Philadelphia-based genetic medicines company, Passage Bio, Inc. (Nasdaq: PASG), has recently made an exciting announcement stating that it has granted inducement awards to new employees. The clinical-stage company, which focuses on developing transformative therapies for central nervous system (CNS) disorders, continues to make strides in its commitment to revolutionizi...

Passage Bio Inc

Passage Bio Inc Announces Operating Deficit for Q2 2023

Heading Towards a Precipice: Passage Bio Inc's Continued Struggles Highlight Risk in the Biotech Sector
The Biotechnology and Pharmaceuticals sector has been a mixed bag this year, with some major companies outperforming expectations while others have faced major challenges. Amidst the spotlight on these industry giants, it is important not to overlook the less prominent players who are also grappling with significant hurdles. One such company is Passage Bio Inc (PASG), which continues to face mounting issues, as evidenced by its recent financial report.
During the second quarter of 2023, Passage Bio Inc announced an operating deficit of a staggering $-25.388 million. This figure far exceeds the deficit reported during the same period in the previous year, and highlights the concerning trajectory of the company's financial performance. While Passage Bio Inc operates primarily in the expansion stage, this report reveals that it is struggling to establish a viable business model. Despite this, the company has managed to slightly reduce its deficit for the fiscal interval ending June 30, 2023, recording a reduced deficit of $-23.856 million compared to the $-39.542 million reported in the second quarter of 2022.

Passage Bio Inc

Passage Bio Inc's Disappointing Q1 Performance: Net Loss of $128 Million Sends Shockwaves Through Healthcare Sector

Passage Bio Inc is a major player in the healthcare sector and has been on the radar of both investors and analysts for some time now. However, the company has yet to deliver on its promises, with a net loss of $-128 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on assets (ROA) of -49.75%, which is a significant disappointment.
While the healthcare sector has seen plenty of successes, it appears that Passage Bio Inc is not keeping pace. The company's return on assets is lower than that of 461 other healthcare companies, which is not a good sign.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com